Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 39 for:    peyronies
Previous Study | Return to List | Next Study

Fractionated Carbon Dioxide Laser Therapy for Treatment of Peyronie's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04326465
Recruitment Status : Recruiting
First Posted : March 30, 2020
Last Update Posted : May 6, 2021
Sponsor:
Information provided by (Responsible Party):
Ryan Flannigan, MD, University of British Columbia

Brief Summary:
This is a pilot study that evaluates the use of Fractional Carbon Dioxide Laser Therapy in the treatment of Peyronie's Disease. Study participants will be assigned to receive Fractional Carbon Dioxide Laser Therapy at 10-15% laser density coverage.

Condition or disease Intervention/treatment Phase
Peyronies Disease Device: Fractional Carbon Dioxide Laser Therapy at 10-15% Laser Density Coverage Not Applicable

Detailed Description:

Peyronie's Disease is a fibrosing disorder of the penis where scar tissue known as a "plaque" forms along the shaft of the penis. This plaque can lead to penile deformity, erectile dysfunction and pain during intercourse. Furthermore, Peyronie's Disease has been shown to negatively affect the quality of life and cause psychosocial distress. Currently, treatments for Peyronie's Disease are invasive (injections or surgery). This study investigates the use of a non-invasive and extra-dermal Fractional Carbon Dioxide Laser Therapy to treat chronic phase Peyronie's Disease.

Fractional Carbon Dioxide Laser Therapy works by destroying and reducing abnormal collagen (a major component found in Peyronie's Disease plaques) in scarred tissue. Although Fractional Carbon Dioxide Lasers have yet to be used in the field of urology, it has already been used safely and successfully to treat conditions similar to Peyronie's Disease (ie. hypertrophic burn scars).

Study participants enrolled in this study will be required to attend 6 study visits. The first study visit is a 'Screening Visit'. At this visit, a medical history and baseline penile measurements (degree of curvature, stretched length, and circumference deformity at flaccid and erect states) will be collected. Study participants will also be asked to complete the International Index of Erectile Function Questionnaire and Peyronie's Disease Questionnaire.

Following the 'Screening Visit', study participants will be scheduled for three Fractional Carbon Dioxide Laser Therapy sessions. These sessions will be scheduled once every six weeks (totalling 12 weeks from the first therapy session).

Following, the last Fractional Carbon Dioxide Laser Therapy session, there will be three follow-up appointments (Week 18, Week 24, Week 52). At these visits, post-therapy penile measurements, International Index of Erectile Function, and Peyronie's Disease scores will be collected.

Digital photographs may be taken as part of the study's analysis and to track the progress of Fractional CO2 Laser Therapy. You will have the option to deny any digital photography.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Efficacy and safety trial for Fractional CO2 Laser Therapy with pre- and post-treatment comparisons (3 laser therapy sessions over 12 weeks in men with Peyronie's Disease).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Fractionated Carbon Dioxide Laser Therapy for Treatment of Peyronie's Disease
Actual Study Start Date : May 1, 2021
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Fractional CO2 Laser Therapy at 10-15% Laser Density Coverage
Study participants with Peyronies Disease will be treated with a Fractional Carbon Dioxide Laser set at a 10-15% laser density. The patient will receive three laser therapy sessions over 12 weeks (one session every four weeks). Following each session, topical triamcinolone will be applied to the treated area.
Device: Fractional Carbon Dioxide Laser Therapy at 10-15% Laser Density Coverage
Fractional Carbon Dioxide Laser Therapy is an ablative therapy where abnormal collagen in scarred tissue is destroyed to permit the formation of more organized collagen. Previous studies have demonstrated its efficacy in treating medical conditions (ex. hypertrophic scars) similar to Peyronies Disease. There is evidence that Fractional Carbon Dioxide Laser Therapy has the ability to target and alter the molecular pathways that are similar to the ones that lead to Peyronie's Disease.




Primary Outcome Measures :
  1. Measured reduction in penile curvature [ Time Frame: Change in penile measurements (Baseline vs. Week 18, 24, & 52). ]
    Penile measurements will be collected at erect states. Penile measurements will be conducted at the screening visit (Baseline) and at the follow-up study visits (Week 18, 24, & 52).


Secondary Outcome Measures :
  1. International Index of Erectile Function Questionnaire [ Time Frame: Change in International Index of Erectile Function Questionnaire score (Baseline vs. Week 18, 24, & 52). ]
    Self-reported 15-item questionnaire that assesses erectile dysfunction. Each item is scored from 0 to 5, yielding a total of 0 to 75.

  2. Peyronie's Disease Questionnaire [ Time Frame: Change in Peyronie's Disease Questionnaire score (Baseline vs. Week 18, 24, & 52). ]
    Self-reported 15-item questionnaire that assesses sexual function in individuals with Peyronie's Disease. Scoring of each item is varied (ie. Q1 scored 0 to 4, Q9 scored 0 to 10)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Healthy males age 18 or older in a stable relationship with a female partner/spouse (for at least 3 months and willing to have vaginal intercourse with that female partner/spouse.
  2. Diagnosis of Peyronie's Disease for at least 12 months with evidence of stable disease as determined by the investigator.
  3. Penile curvature of 30º-90º in the dorsal, lateral, or dorsal/lateral plane (must have been possible to delineate the single plane of maximal curvature for evaluation).
  4. Signed informed Ethics-approved consent agreement; signed authorization form to allow disclosure of protected information.
  5. Ability to read, complete, and understand the various rating instruments in English.

Exclusion Criteria:

  1. Penile curvature of <30º or >90º.
  2. Any conditions affecting the penis such as a chordee in the presence or absence of hypospadias; thrombosis of the dorsal penile artery; infiltration by a benign or malignant mass or an infectious agent; ventral curvature from any cause; presence of an active sexually transmitted disease; known active hepatitis B or C; known immune deficiency disease (including Human Immunodeficiency Virus).
  3. Failure to achieve a sufficient erection (after prostaglandin or Trimix administration), in the opinion of the investigator, to accurately measure the penile deformity.
  4. Calcified plaque as evident by appropriate radiographic evaluation, i.e. penile ultrasound that would prevent treatment with Fractional Carbon Dioxide Laser.
  5. Isolated hourglass deformity of the penis without curvature.
  6. Treatment or plans to undergo treatment for Peyronie's Disease, including but not limited to any previous surgery, oral/topical agents within 3 months, intralesional medical therapies within 3 months, extracorporeal shock wave therapy within 6 months, or use of mechanical devices within 2 weeks before the start of the study.
  7. Use of or plans to use a mechanical devices to induce a passive erection within 2 weeks before the start of study.
  8. Erectile dysfunction that was unresponsive to Phosphodiesterase inhibitors.
  9. Received an investigation drug or treatment within 30 days before start of the study.
  10. At any time, received Collagenase clostridium histolyticum for the treatment of Peyronie's Disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04326465


Contacts
Layout table for location contacts
Contact: Justin Chan, BMSc 778-887-1339 justinyhchan@alumni.ubc.ca

Locations
Layout table for location information
Canada, British Columbia
Diamond Health Care Centre Recruiting
Vancouver, British Columbia, Canada, V5Z1M9
Contact: Ryan Flannigan, MD    6048755003    clinic@ubcurology.com   
Sponsors and Collaborators
University of British Columbia
Investigators
Layout table for investigator information
Principal Investigator: Ryan Flannigan, MD UBC Faculty of Medicine - Department of Urologic Sciences
Layout table for additonal information
Responsible Party: Ryan Flannigan, MD, Assistant Professor, University of British Columbia
ClinicalTrials.gov Identifier: NCT04326465    
Other Study ID Numbers: H18-02482
First Posted: March 30, 2020    Key Record Dates
Last Update Posted: May 6, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Ryan Flannigan, MD, University of British Columbia:
Peyronies Disease
Fractionated Carbon Dioxide Laser
Additional relevant MeSH terms:
Layout table for MeSH terms
Penile Induration
Penile Diseases
Connective Tissue Diseases